ArticleBMJ open respiratory research2025
Assessment of the clinical prognosis of patients with chronic obstructive pulmonary disease using combined blood and sputum eosinophil counts.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh blood or sputum eosinophil counts are linked to poor clinical outcomes in chronic obstructive pulmonary disease (COPD), yet the value of combining both for the assessment of clinical prognosis remains unclear. In this study, we explore the value of combined blood and sputum eosinophil counts for assessing COPD outcomes.
methodsPatients were divided into four groups by blood (≥300 cells/µL) and sputum (≥3%) eosinophil counts (low blood and low sputum, low blood and high sputum, high blood and low sputum, high blood and high sputum). Spirometry, questionnaires, CT scans, impulse oscillometry, blood laboratory tests and induced sputum tests were performed at baseline. Spirometry and follow-up questionnaires were performed annually. Poisson regression was used to compute the relative risk (RR) for acute exacerbation. The mixed-effects model was used to assess annual lung function decline.
resultsCompared with the low blood and low sputum eosinophils group, the high blood and high sputum eosinophils group had poorer lung function, more severe airway resistance and worse emphysema and air trapping at baseline. The high blood and high sputum eosinophils group had higher risks of cough (adjusted OR=1.87, 95% CI 1.20 to 2.92, p=0.006) and wheezing (adjusted OR=2.19, 95% CI 1.32 to 3.64, p=0.002). The low blood and high sputum eosinophils group had higher risks of phlegm (adjusted OR=1.53, 95% CI 1.04 to 2.24, p=0.029) and dyspnoea (adjusted OR=1.68, 95% CI 1.13 to 2.50, p=0.010). The high blood and high sputum eosinophils group demonstrated higher total (adjusted RR=1.36, 95% CI 1.15 to 1.60, p<0.001) and moderate-to-severe (adjusted RR=1.42, 95% CI 1.14 to 1.76, p=0.001) exacerbation risks. There was no significant difference in annual lung function decline among the groups.
conclusionElevated blood and sputum eosinophil counts are linked to worse lung function and a higher exacerbation risk in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.